A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE

In randomized clinical trials, the androgen‐receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration‐resistant prostate cancer (mCRPC). This study captured efficacy, safety and patient‐reported outcomes (PROs) of enzalutamide in mCRPC patients in a real‐world Eur...

Descripción completa

Detalles Bibliográficos
Autores principales: Payne, Heather, Robinson, Angus, Rappe, Bernard, Hilman, Serena, De Giorgi, Ugo, Joniau, Steven, Bordonaro, Roberto, Mallick, Stéphane, Dourthe, Louis‐Marie, Flores, Moisés Mira, Gumà, Josep, Baron, Benoit, Duran, Aurea, Pranzo, Alessandra, Serikoff, Alexis, Mott, David, Herdman, Mike, Pavesi, Marco, De Santis, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298797/
https://www.ncbi.nlm.nih.gov/pubmed/34648657
http://dx.doi.org/10.1002/ijc.33845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298797/
https://www.ncbi.nlm.nih.gov/pubmed/34648657
http://dx.doi.org/10.1002/ijc.33845

Ejemplares similares